DarioHealth (NASDAQ:DRIO) and iCAD (NASDAQ:ICAD) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, valuation, risk, institutional ownership, profitability, analyst recommendations and dividends.

Valuation and Earnings

This table compares DarioHealth and iCAD’s gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
DarioHealth $7.39 million 2.37 -$17.80 million N/A N/A
iCAD $25.62 million 4.92 -$9.02 million ($0.38) -17.24

iCAD has higher revenue and earnings than DarioHealth.

Institutional and Insider Ownership

19.0% of DarioHealth shares are held by institutional investors. Comparatively, 19.0% of iCAD shares are held by institutional investors. 22.7% of DarioHealth shares are held by company insiders. Comparatively, 10.1% of iCAD shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Profitability

This table compares DarioHealth and iCAD’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
DarioHealth -257.11% -296.31% -169.04%
iCAD -36.24% -54.45% -14.58%

Analyst Ratings

This is a summary of current ratings for DarioHealth and iCAD, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
DarioHealth 0 0 1 0 3.00
iCAD 0 0 0 0 N/A

DarioHealth presently has a consensus target price of $1.50, indicating a potential upside of 226.09%. Given DarioHealth’s higher possible upside, equities research analysts clearly believe DarioHealth is more favorable than iCAD.

Risk & Volatility

DarioHealth has a beta of -0.67, suggesting that its stock price is 167% less volatile than the S&P 500. Comparatively, iCAD has a beta of 1.04, suggesting that its stock price is 4% more volatile than the S&P 500.

Summary

iCAD beats DarioHealth on 8 of the 11 factors compared between the two stocks.

DarioHealth Company Profile

DarioHealth Corp., a digital health company, develops and commercializes patented and proprietary technologies providing consumers with laboratory-testing capabilities using smart phones and other mobile devices in the United States, Europe, Australia, and Canada. The company's flagship product, Dario, also known as Dario Smart Diabetes Management Solution, is a mobile, real-time, cloud-based, diabetes management solution based on a software application combined with Dario Smart Meter, a pocket-sized, blood glucose monitoring device. It offers Dario Engage software platform, where the company digitally engages with Dario users and assists them in monitoring their chronic illnesses, as well as provides them with coaching, support, digital communications, and real time alerts, trends, and pattern analysis. DarioHealth Corp. markets its products directly to consumer cash sales, as well as retail pharmacy and distributors; and through e-stores. The company was formerly known as LabStyle Innovations Corp. and changed its name to DarioHealth Corp. in July 2016. DarioHealth Corp. was founded in 2011 and is headquartered in Caesarea, Israel.

iCAD Company Profile

iCAD, Inc. provides image analysis, workflow solutions, and radiation therapy for the early identification and treatment of cancer in the United States and internationally. It operates through two segments, Cancer Detection and Cancer Therapy. The company provides electronic brachytherapy (eBX) products, including Axxent eBx systems for the treatment of early stage breast cancer, endometrial cancer, cervical cancer, and skin cancer, as well as for treating other cancers or conditions where radiation therapy is indicated comprising intraoperative radiation therapy. It also offers digital mammography computer-aided detection (CAD) products, such as advanced image analysis and workflow solutions in breast imaging, which include PowerLook Mammo Detection, which detects and identifies suspicious masses and micro-calcifications; and PowerLook Advanced Mammography Platform, a computer server residing on a customer's network that receives patient studies from the imaging modality, performs CAD and density assessment analysis, and sends the CAD results to picture archiving and communication system and/or review workstations. In addition, the company's digital mammography CAD products comprise magnetic resonance imaging products to detect breast and prostate cancer; breast tomosynthesis systems; and advanced image analysis and workflow solutions in computed tomography (CT) colonography, including VeraLook that supports the detection of colonic polyps in conjunction with CT colonography. It serves hospitals, ambulatory care centers and free standing radiation oncology facilities, and other office-based uses through sales organizations, as well as through various original equipment manufacturer partners, distributors, and resellers. iCAD, Inc. has a strategic partnership agreement with Invivo Corp. The company was formerly known as Howtek, Inc. and changed its name to iCAD, Inc. in June 2002. iCAD, Inc. was founded in 1984 and is headquartered in Nashua, New Hampshire.

Receive News & Ratings for DarioHealth Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DarioHealth and related companies with MarketBeat.com's FREE daily email newsletter.